Yueping Zeng

Dr. Yueping Zeng

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2023 in Dermatology
Verified
Journal Article
Open access
PDF file
ZSZheng Su
Zheng Su
YZYueping Zeng
Yueping Zeng
Background: Dupilumab is the first approved IL-4Rα inhibitor for the treatment of atopic dermatitis at present with good efficacy and safety. However, there have been several reports of psoriasis and psoriasiform manifestations occurring after dupilumab therapy in recent years, showing a new paradoxical cutaneous reaction associated with biologics. Summary: This is a scoping review in order to summarize the demographics and epidemiology, clinical manifestations, diagnosis, potential pathogenesis, and promising management of dupilumab-associated psoriasis and psoriasiform manifestations.

21 July 2010 in Gerontology
Verified
Journal Article
Closed access
JCJinbo Chen
Jinbo Chen
LLLi Li
Li Li
JCJiang Chen
Jiang Chen
YZYueping Zeng
Yueping Zeng
HXHaoxiang Xu
Haoxiang Xu
BWBaoxi Wang
Baoxi Wang
Background: Bullous pemphigoid (BP) is an acquired autoimmune dermatosis that is often associated with various neurological diseases (ND) in the elderly. Previously, we reported that BP antigen 1 (BPAG1) of the mouse brain can be recognized by serum samples of BP patients with ND (BP+ND), indicating the possibility that BPAG1 could act as a shared autoantigen of the skin and brain. However, it is not known whether the serum of BP+ND patients could recognize BPAG1 in the human brain. Objectives: The aim of this study is to determine whether sera of BP+ND patients could recognize BP antigens in human brain tissue. Methods: Serum samples of BP+ND patients and those of age- and sex-matched BP patients without ND, ND patients without BP, and normal controls were obtained. Serum samples were examined by immunoblotting against protein extracts of human skin and brain. Results: A 230-kDa protein of human epidermal extract was recognized by 16 of 22 (72.7%) serum samples of elderly BP+ND patients, whereas it was recognized by 50, 0, and 0% of serum samples of BP, ND, and controls, respectively. A 230-kDa protein of human brain extract was recognized by 12 of 22 (54.5%) serum samples of BP+ND patients, whereas it was recognized by 9.1, 9.1, and 4.5% of serum samples of BP, ND, and controls, respectively. A 180- and a 165-kDa protein could also be recognized by a proportion of serum samples of BP and BP+ND patients. Conclusion: This study demonstrated that both human skin and brain contain immunogenic BPAG1 in BP+ND patients. We speculate that alterations of the central nervous system in the course of pathological changes of elderly ND patients could expose the neural isoforms of BPAG1 or other BP antigens. Autoantibodies against these antigens in the brain may cross-react with antigen in the skin, which may underlie the pathological development of BP.

19 June 2025 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
CSChen Sun
Chen Sun
XZXuan Zhang
Xuan Zhang
ZSZheng Su
Zheng Su
WYWen-Hui Yao
Wen-Hui Yao
HCHongda Chen
Hongda Chen
YZYueping Zeng
Yueping Zeng

20 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
LZLishan Zhang
Lishan Zhang
XWXueyi Wen
Xueyi Wen
YHYibo Hou
Yibo Hou
YYYongshi Yang
Yongshi Yang
WSWei Song
Wei Song
Jin-Lyu SunJin-Lyu Sun
Jin-Lyu Sun
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. Dupilumab, a monoclonal antibody that targets the interleukin (IL)-4 and IL-13 receptors, has been widely used in AD because of its efficacy. However, metabolic changes occurring in patients with AD in response to dupilumab remains unknown. In this study, we integrated metabolomics and lipidomics analyses with clinical data to explore potential metabolic alterations associated with dupilumab therapeutic efficacy. In addition, we investigated whether the development of treatment side effects was linked to the dysregulation of metabolic pathways.Methods: A total of 33 patients with AD were included in the current study, with serum samples collected before and after treatment with dupilumab. Comprehensive metabolomic and lipidomic analyses have previously been developed to identify serum metabolites (including lipids) that vary among treatment groups. An orthogonal partial least squares discriminant analysis model was established to screen for differential metabolites and metabolites with variable importance in projection > 1 and p < 0.05 were considered potential metabolic biomarkers. MetaboAnalyst 5.0 was used to identify related metabolic pathways. Patients were further classified into two groups, well responders (n = 19) and poor responders (n = 14), to identify differential metabolites between the two groups.Results: The results revealed significant changes in serum metabolites before and after 16 weeks of dupilumab treatment. Variations in the metabolic profile were more significant in the well-responder group than in the poor-responder group. Pathway enrichment analysis revealed that differential metabolites derived from the well-responder group were mainly involved in glycerophospholipid metabolism, valine, leucine and isoleucine biosynthesis, the citrate cycle, arachidonic acid metabolism, pyrimidine metabolism, and sphingolipid metabolism.Conclusion: Serum metabolic profiles of patients with AD varied significantly after treatment with dupilumab. Differential metabolites and their related metabolic pathways may provide clues for understanding the effects of dupilumab on patient metabolism.

1 June 2012 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
LLLi Li
Li Li
YZYueping Zeng
Yueping Zeng
KFKai Fang
Kai Fang
YXYu Xiao
Yu Xiao
HJHongzhong Jin
Hongzhong Jin
JCJiang Chen
Jiang Chen
Pilomatricoma is a common benign neoplasm of the skin characterized by a solid cutaneous nodule of hair matrix origin. The anetodermal or lymphangiectatic variant of pilomatricoma is rare, and its bullous appearance is often associated with attenuated collagen and elastic fibrils and dilated lymphatic vessels in the overlying dermis. However, the tumors of anetodermic pilomatricoma have never been characterized at the molecular level, and the exact mechanism for their development is unknown. In this study, we evaluated histological and molecular features of a bullous pilomatricoma along with 5 control tumors and determined that tumors of both anetodermic and control pilomatricoma comprise similar molecular features, such as nuclear lymphoid enhancer binding factor 1 (LEF1) localization and the expression of keratins. In addition, we associated the development of the anetodermic pilomatricoma with mechanical trauma, scar tissue formation, and increased numbers of blood and lymphatic vessels. This study suggests that the development of the anetodermic form of pilomatricoma is unlikely to be associated with the intrinsic properties of the tumor but with the mechanical trauma that disrupts the dermal integrity and vascular microenvironment.

15 September 2025 in Clinical and Translational Allergy
Verified
Journal Article
Open access
CLChen‐Xi Liu
Chen‐Xi Liu
LLLi Li
Li Li
YZYueping Zeng
Yueping Zeng
Background: Atopic Dermatitis (AD) is a chronic inflammatory skin condition characterized by intensely itchy eczematous lesions and dryness. Recent epidemiological studies have indicated a notable increase in the prevalence of AD in industrialized countries, suggesting that air pollution may significantly influence the onset and progression of AD.Body: This review primarily describes the mechanistic roles of major air pollutants in the pathogenesis of AD, focusing particularly on oxidative stress, skin barrier dysfunction, and immune dysregulation. Moreover, the potential of targeting these pathways to prevent and manage AD is discussed.Conclusion: Air pollution contributes to the pathogenesis of AD by inducing oxidative stress, skin barrier dysfunction, and immune dysregulation through pathways such as AhR and NF‐κB. Mitigating its impact necessitates both personal protective measures and public health policies. Future research should investigate pollutant‐climate interactions and develop novel therapies targeting these mechanisms.